Safety and Efficacy of Fixed Dose Combination of Glimepiride and Metformin in Type 2 Diabetic Patients in Egypt: A Real-Life Study | ||||
| The Medical Journal of Cairo University | ||||
| Article 56, Volume 86, September, September 2018, Page 2599-2603 PDF (416.75 K) | ||||
| Document Type: Original Article | ||||
| DOI: 10.21608/mjcu.2018.58063 | ||||
 View on SCiNiTO | ||||
| Authors | ||||
| MOHAMED F. ABD AL-AZIZ, M.D.; MANAL ABU SHADY, M.D.; SAMIR ABD EL-HAMID, M.D. | ||||
| The Departments of Internal Medicine Units of Endocrine*, Diabetes & Endocrinology** and Gastroenterology***, Faculty of Medicine, Ain Shams University, Egypt | ||||
| Abstract | ||||
| Abstract Background: Previous reports showed a significant im-provement in the glycemic control of patients with Type 2 Diabetes Mellitus (T2DM) following the use of Glimepiride/ Metformin Fixed-Dose Combination (G/M FDC), with a reasonable safety profile. In this real-life study on Egyptian population, we aim to investigate the safety and effectiveness of G/M FDC among patients with T2DM. Subjects and Methods: The present observational, multi-center study included 1211 T2DM patients from Egypt, for whom the investigator decided to prescribe G/M FDC. Patients started G/M FDC at the beginning of the study or one month earlier, and the combination dose was decided by the investi-gators to reflect the in-practice approach. Data were recorded at the initial assessment visit and six months later. Safety outcomes were measured throughout the course of treatment. Results: At the end of six months follow-up duration, 45.2% of the patients achieved the targeted HbA1c £7% and 79.5% achieved the targeted reduction in HbA1c by ³0.7%. The total percentage of patients who achieved either the targeted HbA1c £7% or reduction in HbA1c ³0.7% were 86.5%, while those who achieved both target HbA1c £7% and reduction in HbA1c ³0.7% constituted 38.3% of the patients. The mean HbA1c level reduced throughout the study period from 8.8±1.3% to 7.3±0.9% at the end sixth month (p<0.001). Hyperglycemia was the most commonly reported adverse events (3.5%), followed by hypoglycemia (1.2%). Conclusion: The prescription of G/M FDC in treating patients with T2DM in Egypt is effective in achieving the targeted glycemic control with tolerable safety profile. | ||||
| Keywords | ||||
| Glimepiride/Metformin – HbA1c – Hypoglycaemia – T2DM | ||||
|
Statistics Article View: 309 PDF Download: 636 |
||||
